Pyxis Oncology, Inc. Payments to Acquire Debt Securities, Available-for-sale
Pyxis Oncology, Inc. (PYXS) reported Payments to Acquire Debt Securities, Available-for-sale of $13.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $3.00M, a 92.70% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $10.99M, a 78.59% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $14.56M, a 38.43% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $107.00M, a 33.17% decline from fiscal 2024.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $160.12M, a 18.65% decline from fiscal 2023.
- Pyxis Oncology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $196.83M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.99M 10-Q · filed 2026-08-13 | $13.99M derived: sum of 3 quarters · filed 2026-08-13 | $28.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.99M 10-Q · filed 2026-05-14 | $10.99M derived: sum of 2 quarters · filed 2026-05-14 | $25.55M derived: sum of 3 quarters · filed 2026-05-14 | $66.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.56M derived: sum of 2 quarters · filed 2026-03-23 | $55.65M derived: sum of 3 quarters · filed 2026-08-13 | $107.00M 10-K · filed 2026-03-23 |
| 2025-09-30 | $14.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $55.65M derived: sum of 2 quarters · filed 2026-08-13 | $107.00M 10-Q · filed 2025-11-03 | $111.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $41.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $92.45M 10-Q · filed 2026-08-13 | $96.82M derived: sum of 3 quarters · filed 2026-08-13 | $120.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $51.35M 10-Q · filed 2026-05-14 | $55.72M derived: sum of 2 quarters · filed 2026-05-14 | $79.36M derived: sum of 3 quarters · filed 2026-05-14 | $118.68M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $28.01M derived: sum of 2 quarters · filed 2026-03-23 | $67.33M derived: sum of 3 quarters · filed 2026-03-23 | $160.12M 10-K · filed 2026-03-23 |
| 2024-09-30 | $23.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $62.95M derived: sum of 2 quarters · filed 2025-11-03 | $155.75M 10-Q · filed 2025-11-03 | $165.97M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $39.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $132.10M 10-Q · filed 2025-08-14 | $142.33M derived: sum of 3 quarters · filed 2025-08-14 | $198.76M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $92.79M 10-Q · filed 2025-05-15 | $103.02M derived: sum of 2 quarters · filed 2025-05-15 | $159.45M derived: sum of 3 quarters · filed 2025-05-15 | $194.64M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $66.66M derived: sum of 2 quarters · filed 2025-03-18 | $101.84M derived: sum of 3 quarters · filed 2025-03-18 | $196.83M 10-K · filed 2025-03-18 |
| 2023-09-30 | $56.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $91.62M derived: sum of 2 quarters · filed 2024-11-12 | $186.60M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $35.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $130.18M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $94.99M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |